This is the authors' abstract. We don't add key points for this paper.
Purpose of review Most current immunosuppressive drugs have side effects. It is recognized that the mechanisms for such side effects are similar to that responsible for efficacy and reflects undesirable effects of the drug outside of the immune system. In this review, we will discuss recent developments that led to the introduction of a compound selectively targeting immune cells and that appears devoid of classical side effects observed with current immunosuppressive drugs. Recent findings A large number of cytokines exert their effect by binding to receptors that activate the Janus kinase/signal transducer and activator of transcription pathway, so targeting intracellular signaling pathways is a logical strategy. A selective inhibitor of Janus kinase 3 has been generated and is effective for the prevention of transplant rejection in nonhuman primates and other models. Consistent with predictions from murine studies, drug treatment results in significant reductions in numbers of natural killercells and modest reductions in effector memory CD8+ cells. The side-effect profile appears limited to anemia observed only at high exposure. None of the dose-limiting side effects observed with other immunosuppressants that have been linked with early graft rejection and patient demise have been observed with the inhibition of Janus kinase 3. Summary A selective inhibitor of Janus kinase 3 has now been generated. It most likely represents a new class of effective immunosuppressants. Because of its particular mechanism of action - targeting a wide array of immune cells (T, B, and natural killer) - the compound may offer solutions to acute problems as well as chronic allograft rejection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Borie et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: